Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Investor InvestigationConcerning Potential Securities Laws Violations Announced

If you purchased shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Raptor Pharmaceutical
Affected Securities: 
NASDAQ: RPTP

September 25, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares over potential securities laws violations by Raptor Pharmaceutical and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) concerning whether a series of statements by Raptor Pharmaceutical regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Raptor Pharmaceutical Corp. reported that its annual Total Revenue rose from $16.87 million in 2013 to $69.50 million in 2014 and that its respective Net Loss declined from $69.42 million to $52.54 million.

Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) grw from $7.51 per share in April 2014 to as high as $16.00 per share in June 2015.

Then on September 14, 2015, pre-market, Raptor Pharmaceutical Corp reported that RP103, its product candidate for treatment of nonalcoholic steatohepatitis (NASH) in adolescents, failed to achieve its primary endpoint in a Phase IIb study and that based on the results, Raptor Pharmaceutical Corp will cease development of RP103 for NASH.

Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) declined to as low as $6.82 per share on September 14, 2015.